Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma - PubMed
- ️Mon Jan 01 2024
doi: 10.1007/s12032-023-02265-6.
Liting Yu # 1 , Xiaoli Sun # 1 2 , Junmei Hao 3 , Wenning Shi 1 , Haojie Sun 1 , Xiangji Guo 1 , Xikang Jia 1 , Tianli Liu 1 , Dao-Lai Zhang 1 , Lianqin Li 4 , Hongmei Wang 5 , Cong Xu 6
Affiliations
- PMID: 38177789
- DOI: 10.1007/s12032-023-02265-6
Exploring the role of PRDX4 in the development of uterine corpus endometrial carcinoma
Ping Lei et al. Med Oncol. 2024.
Abstract
Peroxicedoxin 4 (PRDX4), a member of the peroxicedoxins (PRDXs), has been reported in many cancer-related studies, but its role in uterine corpus endometrial carcinoma (UCEC) is not fully understood. In the present study, we found that PRDX4 was highly expressed in UCEC tissues and cell lines through the combination of bioinformatics analysis and experiments, and elevated PRDX4 levels were associated with poor prognosis. Knockdown of PRDX4 significantly blocked the proliferation and migration of the UCEC cell line Ishikawa and reduced degree of cell confluence. These findings highlight the oncogenic role of PRDX4 in UCEC. In addition, genes that interact with PRDX4 in UCEC were MT-ATP8, PBK, and PDIA6, and we speculated that these genes interacted with each other to promote disease progression in UCEC. Thus, PRDX4 is a potential diagnostic biomarker for UCEC, and targeting PRDX4 may be a potential therapeutic strategy for patients with UCEC.
Keywords: Bioinformatics analysis; Biomarkers; Cancer; Peroxicedoxins; Uterine corpus endometrial carcinoma.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Tian Y, Wen F, Wang S, Lv N. Tian Y, et al. Clinics (Sao Paulo). 2022 Sep 15;77:100103. doi: 10.1016/j.clinsp.2022.100103. eCollection 2022. Clinics (Sao Paulo). 2022. PMID: 36116266 Free PMC article.
-
Jiang N, Li D, Han Y, Luo ZG, Liu LB. Jiang N, et al. Aging (Albany NY). 2024 Jun 6;16(11):9784-9812. doi: 10.18632/aging.205899. Epub 2024 Jun 6. Aging (Albany NY). 2024. PMID: 38848146 Free PMC article.
-
Han L, Li Y, Yu Y, Liu G, Gao X, Wang F, Chen W, Xu H, Zhang B, Xu Y, Pan Y, Huang Y, Yi P. Han L, et al. Front Immunol. 2024 Oct 9;15:1454730. doi: 10.3389/fimmu.2024.1454730. eCollection 2024. Front Immunol. 2024. PMID: 39445012 Free PMC article.
-
A comprehensive analysis of CEBPA on prognosis and function in uterine corpus endometrial carcinoma.
Wang J, Huang W, Chai S, Gan J, Zeng Y, Long P, Pang L. Wang J, et al. Sci Rep. 2024 Oct 10;14(1):23773. doi: 10.1038/s41598-024-74242-6. Sci Rep. 2024. PMID: 39390018 Free PMC article.
-
Chen R, An J, Wang Y, Yang L, Lin Q, Wang Y. Chen R, et al. Medicine (Baltimore). 2023 Apr 14;102(15):e33536. doi: 10.1097/MD.0000000000033536. Medicine (Baltimore). 2023. PMID: 37058060 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
- 81901548/National Natural Science Foundation of China
- ZR2019BC078/Natural Science Foundation of Shandong Province
- BY2022KYQD27/Research start-up funding from Binzhou medical university
- S202110440032/Provincial-level Innovative Entrepreneurship Training Program for college students
- 202210440029/National-level Innovative Entrepreneurship Training Program for college students
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous